Combination of carbohydrate antigen 19-9 level and tumor size after neoadjuvant chemoradiation therapy may predict early recurrence of resectable pancreatic ductal adenocarcinoma
- 16 October 2023
- journal article
- research article
- Published by Elsevier in Pancreatology
- Vol. 23 (8) , 970-977
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years AfterSurgery, 2017
- Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched AnalysisJournal of Clinical Oncology, 2017
- Preoperative predictors for early recurrence of resectable pancreatic cancerWorld Journal of Surgical Oncology, 2017
- Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)The Lancet, 2016
- Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective studyPancreatology, 2015
- Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2015
- Is a Preoperative Assessment of the Early Recurrence of Pancreatic Cancer Possible after Complete Surgical Resection?Gut and Liver, 2014
- Pathological and clinical impact of neoadjuvant chemoradiotherapy using full‐dose gemcitabine and concurrent radiation for resectable pancreatic cancerJournal of Hepato-Biliary-Pancreatic Sciences, 2012
- Novel postoperative adjuvant strategy prevents early hepatic recurrence after resection of pancreatic cancerJournal of Hepato-Biliary-Pancreatic Sciences, 2010
- Classification of Surgical ComplicationsAnnals of Surgery, 2004